NanoViricides, Inc. Reports That NNVC is in the Preliminary Additions List of The Russell Global, The Russell 3000, The Russell 2000 and the Russell Microcap Indexes

WEST HAVEN, CONNECTICUT -- June 16th, 2014 -- NanoViricides, Inc. (NYSE MKT: NNVC) reports that NanoViricides, Inc. is in the preliminary list for addition to the Russell Global, Russell 3000, Russell 2000, and Russell Microcap Indexes when Russell Investments ("Russell") reconstitutes its U.S. and global equity indexes on June 27, 2014. The preliminary additions and deletions for the Russell Global, Russell 3000® and Russell Microcap® Indexes were listed on the Russell website on Friday, June 13, 2014, after the U.S. stock market closed ( Russell will provide further updates on Friday, June 20 and 27. The newly reconstituted Russell indexes will take effect after the US stock market close on Friday, June 27.

The most popular of these indexes is called the Russell 2000, a small-cap index, in existence for over 30 years. According to the Russell website, it "has been widely adopted by both institutional and retail investors for measuring performance of the small cap U.S. equity market, due to its accurate, comprehensive methodology". The Russell 2000 is a part of the Russell 3000 that additionally includes the Russell 1000 companies. The latter is an index of the 1000 largest publicly-traded companies. More information about the Russell family of indexes can be found at

The Company believes that this addition to Russell indexes is very significant in that it will give NanoViricides much greater visibility in the financial community. The Company has been informed that JPMorgan and Deutsche Bank investment banks have recently published reports that state an estimated total of 3,378,000 shares of NNVC could be purchased in the near term by various index-based funds, if the Company is added to the Russell indexes in their final June 2014 annual reconstitution.

About NanoViricides
NanoViricides, Inc. ( is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

FDA refers to US Food and Drug Administration. EMA refers to the European Union’s office of European Medical Agency.

NanoViricides, Inc.
Amanda Schuon, 310-550-7200